Breaking Barriers in Oral Targeted Modalities
Faster. Smarter. Safer.
Targeted protein degraders (TPDs), such as molecular glues and PROTACS, are amongst the fastest-growing therapies in the pharmaceutical industry. Success depends on solving the inherent delivery challenges of these molecules, which include solubility, permeability, and overall bioavailability.
At PCI, we make sure those barriers don’t slow you down.
The Market Outlook
The oral targeted therapies market is projected to grow at a CAGR of 20%+ over the next decade. Success belongs to innovators who can overcome delivery barriers, and to CDMOs with the expertise and partnerships to make it happen.
Your Challenge
70–80% of new small molecules are poorly soluble.
TPDs are known as “brick dust” molecules, due to their inherent solubility and permeability challenges.
70–80% of new small Low bioavailability limits the effectiveness of breakthrough therapies from reaching patients. are poorly soluble.
Low bioavailability limits the effectiveness of breakthrough therapies from reaching patients.
The PCI Solution: Product-First, Platform-Agnostic
We put your molecule first, designing the best pathway to clinic and beyond. With PCI, you gain:
Reduced Development Timelines
Our Single Point of Contact (SPOC) model integrates enabling technology partners into one seamless framework. That means fewer handoffs, less waiting, and faster movement from drug substance to patient-ready product.
Speed to Clinic
SmartFHD™ can deliver First-in-Human trials in as little as four months, giving you a decisive head start in competitive pipelines.
Tailored Technology Access
Platform-agnostic selection from spray drying, hot melt extrusion, nanomilling, and micronization, ensuring you get the right solution for your molecule.
Confidence in Complex Molecules
High potent containment down to 10ng/m³ (OEB5), integrated packaging, and analytical services ensure your molecule is handled with precision and safety at every step.
Global Reach, Local Agility
Platform-agnostic selection from spray drying, hot melt extrusion, nanomilling, and Clinical supply and distribution across the US, Europe, Asia, and Australia, backed by a proven regulatory track record with FDA, EMA, MHRA, ANVISA and more., ensuring you get the right solution for your molecule.
What This Means for You
Fewer lost time in development, faster path to market.
Lower risk of costly delays or rework.
Direct access to world-class expertise without managing multiple vendors.
Confidence that your program will advance – from development to commercialization – as quickly and efficiently as possible.
Let’s Accelerate Your Success
Partner with PCI today to break barriers, reduce timelines, and deliver your life changing therapies to patients faster.
